Insider Selling: Solid Biosciences (NASDAQ:SLDB) CTO Sells 2,701 Shares of Stock

Solid Biosciences CTO Paul Herzich sold 2,701 shares at $5.11 each, totaling $13,802.11, reducing his position by 9.21%. Post-sale, he owns 26,622 shares valued at $136,038.42. The sale was disclosed in an SEC filing. SLDB stock rose to $5.92, with a market cap of $461.23 million. Analysts have mixed ratings, with a moderate buy consensus and a target price of $14.82. Institutional investors hold 81.46% of SLDB shares, with significant recent increases in holdings.

Officer Herzich Acquires 4,538 Of Solid Biosciences Inc [SLDB]

Officer Herzich of Solid Biosciences Inc filed a Form 4 with the SEC, disclosing ownership changes: exercised 7,239 shares, surrendered 2,701 shares at $5.11 each, ending with 26,622 shares directly. The surrender was to cover option exercise costs and tax liabilities, executed under a 10b5-1 plan.

Solid Biosciences shares are trading higher after Needham initiated coverage on the stock with a Buy rating and announced a price target of $16.

Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status

Solid Biosciences' SGT-212 has received FDA rare paediatric disease designation, potentially allowing a priority review voucher for future submissions. SGT-212 aims to treat Friedreich’s ataxia by delivering the frataxin gene through dual administration routes. This milestone, along with a fast track designation, accelerates market entry and enhances FDA engagement. The therapy addresses FA's cardiac, neurological, and systemic symptoms, marking progress in meeting unmet needs for this degenerative condition.

Solid Biosciences Receives FDA Rare Pediatric Disease Designation For Sgt-212 Dual Route Of Administration Gene Therapy

Dec 1 (Reuters) - Solid Biosciences Inc:* SOLID BIOSCIENCES RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR SGT-212 DUAL ROUTE OF ADMINISTRATION GENE THERAPY FOR FRIEDREICH’S ATAXIA Source text: Further company coverage: